YARW Stock — Yarrow Bioscience Inc.: Cash, EV, Pipeline

Share price

$29.29

Market cap

$272.5M

Cash

$22.9M

Enterprise value

$249.6M

Balance sheet

Cash	$22.9M
Debt	$0.0M
Net cash	$22.9M
Enterprise value	$249.6M
Basic shares	9.3M shares
Fully diluted shares	37.3M shares
Fully diluted market cap	$1,092.1M
Cash per share	$2.47

Cash figures as of 2026-09-14. Database snapshot: 2026-09-21.

Price history

Loading YARW daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	Experimental: YB-101	Phase 2	Graves' Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

YB-101

Stage not disclosed · Active Modality: Humanized monoclonal antibody

Aliases also known as GenSci098 (and GS-098)

Target TSHR (thyroid-stimulating hormone receptor)

Partnerships Changchun Genescience Pharmaceutical Company, Ltd. (Dec 15, 2025 GenSci License Agreement): exclusive, royalty-bearing license to develop, manufacture and commercialize YB-101 outside Greater China for all fields of use, including GD and TED. Acquired via the Yarrow merger (closed Jul 27, 2026)

Indications

Graves' disease (Stage not disclosed)
Thyroid eye disease (Stage not disclosed)

Status note Lead product candidate; described as clinical-stage in the filing (specific phase not disclosed). Company plans to develop for Graves' disease and explore a clinical development plan for thyroid eye disease.

Repibresib gel

Phase 2 · Active Modality: Topically administered small molecule pan-BD BET inhibitor

Aliases also known as VYN201

Target pan-BD BET

Partnerships Tay Therapeutics (Repibresib License Agreement, Aug 2021): worldwide exclusive license to Tay's pan-BD BET inhibitor compounds in all fields

Status note Former lead program. Phase 2b trial in nonsegmental vitiligo terminated in July 2025 after the trial did not meet its primary endpoint; the extension phase was discontinued. Company is seeking an external partner for continued development.

VYN202

Phase 1 · Active Modality: Oral small molecule BD2-selective BET inhibitor

Target BD2

Partnerships Tay Therapeutics (VYN202 License Agreement, Apr 2023): worldwide exclusive license to Tay's oral BET inhibitor compounds in all fields

Catalysts

— 2026 (2H)

Status note Phase 1b trial in moderate-to-severe plaque psoriasis terminated in July 2025. FDA verbally placed the trial on clinical hold in April 2025 following an observation of testicular toxicity in dogs; the hold was lifted in June 2025 for two doses in female subjects only. A repeat non-clinical toxicology study in male dogs (Oct 2025) is underway to remedy the partial hold in male clinical subjects. Company is evaluating monetization options for the asset.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Experimental: YB-101
Lead indication	Graves' Disease
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07682896	Phase 2	Recruiting	Sponsor	YARW	—	Graves' Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Yarrow Bioscience, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

YARW — Yarrow Bioscience Inc.